tirzepatide cardiovascular Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity

Tirzepatide for Heart Failure in Patients with Obesity

22.47

★★★★☆4.8 (126)

In the SURPASS-CVOT head-to-head trial involving over 13,000 adults with T2D and ASCVD, tirzepatide (Mounjaro) matched dulaglutide in reducing major cardiovascular events (8% lower risk) and significantly cut all-cause mortality by 16%

22.32

★★★★★4.9 (98)

Tirzepatide goes beyond weight loss—supporting heart health, vascular function, and overall metabolic wellness. #Tirzepatide #HeartHealth #MetabolicSupport #Type2Diabetes #CardiovascularHealth #AmaneciaHealth

25.93

★★★★★5.0 (157)

Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity

23.33

★★★★★4.7 (84)

CARDIOVASCULAR EFFICACY OF TIRZEPATIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: AN INDIVIDUAL PARTICIPANT DATA META-ANALYSIS OF 8 RANDOMIZED CLINICAL TRIALS

25.23

★★★★★4.9 (203)

Cardiovascular Outcomes with Tirzepatide Compared with Dulaglutide in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease

24.75

★★★★★5.0 (176)

❇️ Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes 🟠BACKGROUND Tirzepatide, a dual incretin agonist of the glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors, has favorable effects on

22.53

★★★★★4.8 (132)